Jane Street
NPCE icon

Jane Street’s Neuropace NPCE Stock Holding History

Jane Street’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$147K Buy
+11,200
New +$168K ﹤0.01% 10401
2025
Q3 		– Sell
-13,700
Closed -$153K – 11454
2025
Q2 		$153K Buy
+13,700
New +$171K ﹤0.01% 8735

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jane Street's NPCE Position: Q1 2026 in Review

Jane Street reduced its Neuropace (NPCE) stake by 76% in Q1 2026, selling an estimated $1.34M and leaving 28,092 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #8756.

Jane Street first reported a position in NPCE in Q2 2021 and has held it in 6 quarters since. The position peaked at $1.82M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Jane Street held 28,092 shares of Neuropace worth $369K as of Q1 2026.
  • Jane Street sold 89,466 Neuropace shares in Q1 2026, an estimated $1.34M.
  • Neuropace made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8756 holding.
  • Jane Street first reported a position in Neuropace in Q2 2021 and has held it in 6 quarters since.
  • Jane Street's Neuropace position peaked at $1.82M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.